Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03644498 · ClinicalTrials.gov registry record
Study to Determine if the Flu Vaccine Increases the Risk of Muscle Damage in Participants Taking Drugs That Block Certain Proteins Made by Some Types of Immune System Cells
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 1,056
- Enrollment target
NCT03644498 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 1,056 participants.
The verdict
NCT03644498 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 1,056 participants
- Enrollment target
Study Summary
A retrospective, observational study conducted on cancer patients receiving a drug that blocks certain proteins made by some types of immune system cells
Interventions
- OTHER Non-Interventional
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,056 participants |
| Start Date | 2018-05-02 |
| Est. Completion | 2018-10-17 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03644498
The ClinicalTrials.gov registry entry for NCT03644498 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,056 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Non-Interventional is the first listed.
NCT03644498 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03644498 about?
NCT03644498 is a clinical study titled "Study to Determine if the Flu Vaccine Increases the Risk of Muscle Damage in Participants Taking Drugs That Block Certain Proteins Made by Some Types of Immune System Cells". A retrospective, observational study conducted on cancer patients receiving a drug that blocks certain proteins made by some types of immune system cells
What is the current status of trial NCT03644498?
This trial is currently completed. The enrollment target is 1,056 participants. The study started on 2018-05-02. Estimated completion is 2018-10-17.
What interventions are being tested in trial NCT03644498?
The interventions under investigation include: Non-Interventional (OTHER).
Who is sponsoring clinical trial NCT03644498?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.